Quantitative detection of TUSC3 promoter methylation - a potential biomarker for prognosis in lung cancer

  • Authors:
    • Uta Duppel
    • Matthias Woenckhaus
    • Christian Schulz
    • Johannes Merk
    • Wolfgang Dietmaier
  • View Affiliations

  • Published online on: August 1, 2016     https://doi.org/10.3892/ol.2016.4927
  • Pages: 3004-3012
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant promoter methylation of tumor relevant genes frequently occurs in early steps of carcinogenesis and during tumor progression. Epigenetic alterations could be used as potential biomarkers for early detection and for prediction of prognosis and therapy response in lung cancer. The present study quantitatively analyzed the methylation status of known and potential gatekeeper and tumor suppressor genes [O-6-methylguanine-DNA methyltransferase (MGMT), Ras association domain family member 1A (RASSF1A), Ras protein activator like 1 (RASAL1), programmed cell death 4 (PDCD4), metastasis suppressor 1 (MTSS1) and tumor suppressor candidate 3 (TUSC3)] in 42 lung cancers and in corresponding non‑malignant bronchus and lung tissue using bisulfite-conversion independent methylation-quantification of endonuclease-resistant DNA (MethyQESD). Methylation status was associated with clinical and pathological parameters. No methylation was found in the promoter regions of PDCD4 and MTSS1 of either compartment. MGMT, RASSF1A and RASAL1 showed sporadic (up to 26.2%) promoter methylation. The promoter of TUSC3, however, was frequently methylated in the tumor (59.5%), benign bronchus (67.9%) and alveolar lung (31.0%) tissues from each tumor patient. The methylation status of TUSC3 was significantly associated with smaller tumor size (P=0.008) and a longer overall survival (P=0.013). Pooled blood DNA of healthy individuals did not show any methylation of either gene. Therefore, methylation of TUSC3 shows prognostic and pathobiological relevance in lung cancer. Furthermore, quantitative detection of TUSC3 promoter methylation appears to be a promising tool for early detection and prediction of prognosis in lung cancer. However, additional studies are required to confirm this finding.
View Figures
View References

Related Articles

Journal Cover

October-2016
Volume 12 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Duppel U, Woenckhaus M, Schulz C, Merk J and Dietmaier W: Quantitative detection of TUSC3 promoter methylation - a potential biomarker for prognosis in lung cancer. Oncol Lett 12: 3004-3012, 2016
APA
Duppel, U., Woenckhaus, M., Schulz, C., Merk, J., & Dietmaier, W. (2016). Quantitative detection of TUSC3 promoter methylation - a potential biomarker for prognosis in lung cancer. Oncology Letters, 12, 3004-3012. https://doi.org/10.3892/ol.2016.4927
MLA
Duppel, U., Woenckhaus, M., Schulz, C., Merk, J., Dietmaier, W."Quantitative detection of TUSC3 promoter methylation - a potential biomarker for prognosis in lung cancer". Oncology Letters 12.4 (2016): 3004-3012.
Chicago
Duppel, U., Woenckhaus, M., Schulz, C., Merk, J., Dietmaier, W."Quantitative detection of TUSC3 promoter methylation - a potential biomarker for prognosis in lung cancer". Oncology Letters 12, no. 4 (2016): 3004-3012. https://doi.org/10.3892/ol.2016.4927